PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-59.22%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-272.88%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-252.38%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-313.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
10.47%
Share count expansion well above TRVN's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-20.54%
Reduced diluted shares while TRVN is at 0.15%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-64.88%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-57.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16444.97%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-31629.64%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-47124.26%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-24144.03%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-61703.68%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-67595.61%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
1169.73%
Equity/share CAGR of 1169.73% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1236.68%
Equity/share CAGR of 1236.68% while TRVN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-50.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while TRVN stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
88.49%
R&D growth drastically higher vs. TRVN's 44.02%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
34.89%
SG&A growth well above TRVN's 2.46%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.